New arthritis drug seeks Long-Term safety green light
NCT ID NCT07223138
Summary
This study aims to check the long-term safety and effectiveness of an experimental drug called sonelokimab for people with psoriatic arthritis. It is an extension study for about 1,560 participants who have already completed a previous related trial. The main goal is to see how well people tolerate the drug and if it continues to control joint pain, swelling, and skin symptoms over a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Jonesboro, Arkansas, 72401, United States
-
Clinical Site
Upland, California, 91786, United States
-
Clinical Site
Clearwater, Florida, 33765, United States
-
Clinical Site
Duncansville, Pennsylvania, 16635, United States
-
Clinical Site
Memphis, Tennessee, 38119, United States
-
Clinical Site
Lubbock, Texas, 79424, United States
Conditions
Explore the condition pages connected to this study.